Tetraspanins and tumor progression

Clinical and Experimental Metastasis

Volumn 28, Issue 3, 2011, Pages 261-270

  Richardson, Mekel M ^a   Jennings, Lisa K ^a   Zhang, Xin A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Angiogenesis; Cell adhesion; Cell migration; Keywords Tetraspanin; Tumor invasion; Tumor metastasis

Indexed keywords

CD151 ANTIGEN; CD63 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; PROTEIN TSPAN8; TETRASPANIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN;

ANGIOGENESIS; ANTIGEN EXPRESSION; CANCER INVASION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; HUMAN; MEMBRANE STRUCTURE; METASTASIS; MITOGENESIS; NONHUMAN; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; DISEASE COURSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; HUMANS; MEMBRANE MICRODOMAINS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79953309755     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9365-5     Document Type: Review

References (138)

1. Hemler ME, Mannion BA, Berditchevski F (1996) Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1287:67-71 (Pubitemid 26189187)
2. Boucheix C, Duc GH, Jasmin C et al (2001) Tetraspanins and malignancy. Expert Rev Mol Med 2001:1-17
3. Wright MD, Moseley GW, van Spriel AB (2004) Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens 64:533-542 (Pubitemid 39472918)
4. Lazo PA (2007) Functional implications of tetraspanin proteins in cancer biology. Cancer Sci 98:1666-1677 (Pubitemid 47487899)
5. Zöller M (2009) Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9:40-55
6. Sadej R, Romanska H, Baldwin G et al (2009) CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 7:787-798
7. Gesierich S, Berezovskiy I, Ryschich E et al (2006) Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res 66(14):7083-7094 (Pubitemid 44197685)
8. Nazarenko I, Rana S, Baumann A et al (2010) Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 70:1668-1678
9. Boucheix C, Rubinstein E (2001) Tetraspanins. Cell Mol Life Sci 58:1189-1205 (Pubitemid 32844093)
10. Hakomori SI (2002) Inaugural article: the glycosynapse. Proc Natl Acad Sci USA 99:225-232
11. Levy S, Shoham T (2005) Protein-protein interactions in the tetraspanin web. Physiology 20:218-224 (Pubitemid 41215195)
12. Hemler ME (2005) Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6:801-811 (Pubitemid 41726118)
13. Charrin S, le Naour F, Silvie O et al (2009) Lateral organization of membrane proteins: tetraspanins spin their web. Biochem J 420:133-154
14. Yáñez-Mó M, Barreiro O, Gordon-Alonso M et al (2009) Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 19:434-446
15. Szala S, Kasai Y, Steplewski Z et al (1990) Molecular cloning of cDNA for the human tumor-assocaited antigen CO-029 and identification of the related transmembrane antigens. Proc Natl Acad Sci USA 87:6833-6837
16. Claas C, Seiter S, Claas A et al (1998) Association between the rat homologue of CO-029, a metastasis-associated tetraspanin molecule and consumption coagulopathy. J Cell Biol 141: 280-297
17. Kanetaka K, Sakamoto M, Yamamoto Y et al (2001) Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol 35:637-642 (Pubitemid 33078274)
18. Le Naour F, AndŕM, Greco C, Billard M et al (2006) Profiling of the tetraspanin web of human colon cancer cells. Mol Cell Proteomics 5:5845-5857
19. Gesierich S, Paret C, Hildebrand D et al (2005) Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res 11(8):2840-2852 (Pubitemid 40525182)
20. Zhou Z, Ran YL, Hu H et al (2008) TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin Exp Metastasis 25(5):537-548
21. Kanetaka K, Sakamoto M, Yamamoto Y et al (2003) Possible involvement of tetraspanin CO-029 in hematogenous intrahepatic metastasis of liver cancer cells. J Gastroenterol Hepatol 18(11):1309-1314 (Pubitemid 37464007)
22. Claas C, Wahl J, Orlicky DJ et al (2005) The tetraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J 389:99-110 (Pubitemid 40978012)
23. Kuhn S, Koch M, Nübel T et al (2007) A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 5:553-567 (Pubitemid 46985046)
24. Sauer G, Kurzeder C, Grundmann R et al (2003) Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep 10(2):405-410
25. Hashida H, Takabayashi A, Tokuhara T et al (2003) Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer 89:158-167 (Pubitemid 36897952)
26. Ang J, Lijovic M, Ashman LK et al (2004) CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev 11:1717-1721 (Pubitemid 39482947)
27. Yang XH, Richardson AL, Torres-Arzayus MI et al (2008) CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res 68:3204-3213
28. Ke AW, Shi GM, Zhou J et al (2009) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491-503
29. Hirano C, Nagata M, Noman AA et al (2009) Tetraspanin gene expression levels as potential biomarkers for malignancy of gingival squamous cell carcinoma. Int J Cancer 124(12): 2911-2916
30. Novitskaya V, Romanska H, Dawoud M et al (2010) Tetraspanin CD151 regulates growth of mammary epithelial cells in three-dimensional extracellular matrix: implication for mammary ductal carcinoma in situ. Cancer Res 70:4698-4708
31. Tokuhara T, Hasegawa H, Hattori N et al (2001) Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res 7:4109-4114 (Pubitemid 34044635)
32. Shi GM, Ke AW, Zhou J et al (2010) CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 52:183-196
33. Zijlstra A, Lewis J, Degryse B et al (2008) The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13:221-234 (Pubitemid 351318371)
34. Testa JE, Brooks PC, Lin JM et al (1999) Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 59:3812-3820 (Pubitemid 29381891)
35. Kohno M, Hasegawa H, Miyake M et al (2002) CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer 97:336-343 (Pubitemid 34049024)
36. Sadej R, Romanska H, Kavanagh D et al (2010) Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 70:6059-6070
37. Yang XH, Flores LM, Li Q et al (2010) Disruption of lamininintegrin- CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70:2256-2263
38. Hong IK, Jin YJ, Byun HJ, Jeoung DI, Kim YM, Lee H (2006) Homophilic interactions of tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways. J Biol Chem 281:24279-24292 (Pubitemid 44274201)
39. Klosek SK, Nakashiro K, Hara S et al (2005) CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun 336(2):408-416 (Pubitemid 41267245)
40. Winterwood NE, Varzavand A, Meland MN et al (2006) A critical role for tetraspanin CD151 in alpha3beta1 and alpha6-beta4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 17:2707-2721 (Pubitemid 43825507)
41. Shigeta M, Sanzen N, Ozawa M et al (2003) CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization. J Cell Biol 163(1):165-176 (Pubitemid 37271443)
42. Nishiuchi R, Sanzen N, Nada S et al (2005) Potentiation of the ligand-binding activity of integrin alpha3beta1 via association with tetraspanin CD151. Proc Natl Acad Sci USA 102(6): 1939-1944 (Pubitemid 40261991)
43. Johnson JL, Winterwood N, DeMali KA et al (2009) Tetraspanin CD151 regulates RhoA activation and the dynamic stability of carcinoma cell-cell contacts. J Cell Sci 122:2263-2273
44. Hasegawa M, Furuya M, Kasuya Y et al (2007) CD151 dynamics in carcinoma-stroma interaction: integrin expression, adhesion strength and proteolytic activity. Lab Invest 87(9): 882-892 (Pubitemid 47267817)
45. Si Z, Hersey P (1993) Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer 54(1):37-43 (Pubitemid 23136996)
46. Miyake M, Nakano K, Leki Y et al (1995) Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res 55(18):4127-4131
47. Cajot JF, Sordat I, Silvestre T et al (1997) Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 57(13):2593-2597 (Pubitemid 27283764)
48. Mori M, Mimori K, Shiraishi T et al (1998) Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 4(6):1507-1510 (Pubitemid 28265235)
49. Sho M, Adachi M, Taki T et al (1998) Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79(5):509-516 (Pubitemid 28445274)
50. Uchida S, Shimada Y, Watanabe G et al (1999) Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 79(7-8):1168-1173 (Pubitemid 29087892)
51. Kusukawa J, Ryu F, Kameyama T et al (2001) Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J Oral Pathol Med 30(2):73-79 (Pubitemid 32102985)
52. Miyamoto S, Maruyama A, Okugawa K et al (2001) Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers. Cancer 92(3):542-548 (Pubitemid 32735189)
53. Murayama Y, Miyagawa J, Shinomura Y et al (2002) Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 98(4):505-513 (Pubitemid 34208550)
54. Houle CD, Ding XY, Foley JF et al (2002) Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol 86(1):69-78 (Pubitemid 34757054)
55. Erovic BM, Pammer J, Hollemann D et al (2003) Motilityrelated protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 25(10):848-857 (Pubitemid 37139897)
56. Sauer G, Windisch J, Kurzeder C et al (2003) Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9(17):6426-6431 (Pubitemid 38031829)
57. Mhawech P, Herrmann F, Coassin M et al (2003) Motilityrelated protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 98(8):1649-1657 (Pubitemid 37238621)
58. Wang JC, B́gin LR, B́rub́ NG et al (2007) Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res 13(8):2354-2361 [Epub 2007 Apr 3] (Pubitemid 46698584)
59. Yau JC, Dabbagh LK, Formenti KS et al (1998) Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma. Oncol Rep 5(6):1507-1511 (Pubitemid 28474103)
60. De Bruyne E, Bos TJ, Asosingh K et al (2008) Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 14(10):2918-2926
61. Yoon SO, Zhang X, Freedman AS et al (2010) Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol 177(1):377-386
62. Higashiyama M, Taki T, Ieki Y et al (1995) Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 55(24):6040-6044
63. Miyake M, Nakano K, Itoi SI et al (1996) Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56(6):1244-1249 (Pubitemid 26080963)
64. Miyake M, Adachi M, Huang C et al (1999) A novel molecular staging protocol for non-small cell lung cancer. Oncogene 18(14):2397-2404 (Pubitemid 29192718)
65. Mhawech P, Dulguerov P, Tschanz E et al (2004) Motilityrelated protein-1 (MRP-1/CD9) expression can predict diseasefree survival in patients with squamous cell carcinoma of the head and neck. Br J Cancer 90(2):471-475 (Pubitemid 38250647)
66. Woegerbauer M, Thurnher D, Houben R et al (2010) Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma: strong evidence for a posttranscriptional finetuning of CD9 gene expression. Mod Pathol 23(5):751-762
67. Hori H, Yano S, Koufuji K et al (2004) CD9 expression in gastric cancer and its significance. J Surg Res 117(2):208-215 (Pubitemid 38393645)
68. Soyuer S, Soyuer I, Unal D et al (2010) Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy. Pathol Res Pract [Epub ahead of print]
69. Ikeyama S, Koyama M, Yamaoko M et al (1993) Suppression of cell motility and metastasis by transfection with human motilityrelated protein (MRP-1/CD9) DNA. J Exp Med 177(5): 1231-1237 (Pubitemid 23117114)
70. Miyake M, Inufusa H, Adachi M et al (2000) Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery. Oncogene 19(46):5221-5226
71. Zheng R, Yano S, Zhang H et al (2005) CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res 15(7-8): 365-372 (Pubitemid 43198593)
72. Takeda T, Hattori N, Tokuhara T et al (2007) Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res 67(4):1744-1749 (Pubitemid 46383401)
73. Nakamoto T, Murayama Y, Oritani K et al (2009) A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 44(9):889-896
74. Ono M, Handa K, Sonnino S et al (2001) GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: Coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy. Biochemistry 40(21):6414-6421 (Pubitemid 32472731)
75. Funakoshi T, Tachibana I, Hoshida Y et al (2003) Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 22(5):674-687 (Pubitemid 36269281)
76. Mitsuzuka K, Handa K, Satoh M et al (2005) A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9. J Biol Chem 280(42):35545-35553 (Pubitemid 41532746)
77. Fan J, Zhu GZ, Niles RM (2010) Expression and function of CD9 in melanoma cells. Mol Carcinog 49(1):85-93
78. Lafleur MA, Xu D, Hemler ME (2009) Tetraspanin proteins regulate membrane type-1 matrix metalloproteinase-dependent pericellular proteolysis. Mol Biol Cell 20(7):2030-2040
79. Longo N, Yáñez-Mó M, Mittelbrunn M et al (2001) Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 98(13):3717-3726
80. Nakazawa Y, Sato S, Naito M et al (2008) Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 112(5):1730-1739
81. Shallal S, Kornbluth J (2000) CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood 96(1):224-233 (Pubitemid 30456475)
82. Saito Y, Tachibana I, Takeda Y et al (2006) Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res 66(19):9557-9565 (Pubitemid 44623654)
83. Ovalle S, Gutiérrez-López MD, Olmo N et al (2007) The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int J Cancer 121(10):2140-2152 (Pubitemid 47585592)
84. Zvereff V, Wang JC, Shun K et al (2007) Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells. Br J Cancer 97(7):941-948 (Pubitemid 47519309)
85. Sugiura T, Berditchevski F (1999) Function of α3β1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 146:1375-1389 (Pubitemid 29477702)
86. Furuya M, Kato H, Nishimura N et al (2005) Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets. Cancer Res 65(7):2617-2625 (Pubitemid 40490060)
87. Huang CL, Ueno M, Liu D et al (2006) MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2. Oncogene 25(49):6480-6488 (Pubitemid 44607080)
88. Hong IK, Kim YM, Jeoung DI et al (2005) Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK, JNK and c-Jun pathways in human melanoma cells. Exp Mol Med 37(3):230-239
89. Higashiyama S, Iwamoto R, Goishi K et al (1995) The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGFlike growth factor. J Cell Biol 128(5):929-938
90. Imhof I, Gasper WJ, Derynck R (2008) Association of tetraspanin CD9 with transmembrane TGFα confers alterations in cell surface presentation of TGFα and cytoskeletal organization. J Cell Sci 121:2265-2274
91. Atkinson B, Ernst CS, Ghrist BF et al (1985) Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. Hybridoma 4:243-255 (Pubitemid 16220919)
92. Kondoh M, Ueda M, Ichihashi M et al (1993) Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res 3:241-245 (Pubitemid 23289217)
93. Zhijun X, Shulan Z, Zhuo Z et al (2007) Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues. Eur J Gynaecol Oncol 28:179-183 (Pubitemid 46985637)
94. Kwon MS, Shin SH, Yim SH et al (2007) CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer 57:46-53 (Pubitemid 46843337)
95. Adachi M, Taki T, Higashiyama M et al (2000) Significance of integrin alpha5 gene expression as a prognostic factor in nodenegative non-small cell lung cancer. Clin Cancer Res 6:96-101 (Pubitemid 30064981)
96. Liu AY, Roudier MP, True LD (2004) Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165(5):1543-1556 (Pubitemid 39435154)
97. Chen Z, Mustafa T, Trojanowicz B et al (2004) CD82, and CD63 in thyroid cancer. Int J Mol Med 14:517-527
98. Radford KJ, Mallesch J, Hershey P (1995) Suppression of human melanoma cell growth and metastasis by the melanomaassociated antigen CD63 (ME491). Int J Cancer 62:631-635
99. Radford KJ, Thorne RF, Hersey P (1997) Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol 158:3353-3358 (Pubitemid 127484053)
100. Jang HI, Lee H (2003) A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med 35:317-323 (Pubitemid 37152647)
101. Takino T, Miyamori H, Kawaguchi N et al (2003) Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem Biophys Res Commun 304:160-166 (Pubitemid 36434211)
102. Jung KK, Liu XW, Chirco R et al (2006) Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25:3934-3942 (Pubitemid 44338736)
103. Dong JT, Lamb PW, Rinker-Schaeffer CW et al (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-887
104. Tonoli H, Barrett C (2005) CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med 11:563-570 (Pubitemid 41713998)
105. Jackson P, Marreiros A, Russell PJ (2005) KAI1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol 37:530-534 (Pubitemid 40022929)
106. Liu WM, Zhang XA (2006) KAI/CD82, a tumor metastasis suppressor. Cancer Lett 240:183-194
107. Miranti C (2009) Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal 21:196-211
108. Malik FA, Sanders AJ, Jiang WG (2009) KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol 24:519-530
109. Adachi M, Taki T, Ieki Y et al (1996) Correlation of KAI1/CD82 gene expression with good prognosis in patients with nonsmall cell lung cancer. Cancer Res 56:1751-1755 (Pubitemid 26118208)
110. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Issacs JT, Barrett JC (1997) Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics 41:25-32 (Pubitemid 27152817)
111. Yang X, Wei LL, Tang C et al (2001) Overexpression of KAI1 suppresses in vitro invasiveness and in vitro metastasis in breast cancer cells. Cancer Res 61:5284-5288 (Pubitemid 32681565)
112. Abe M, Sugiura T, Takahashi M et al (2008) A novel function of CD82/KAI1 on E-cadherin-mediated homophillic cellular adhesion of cancer cells. Cancer Lett 266:163-170
113. Protzel C, Kakies C, Kleist B et al (2008) Down regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma. Virchows Arch 452:369-375
114. Ruseva Z, Geiger PX, Hutzler P et al (2009) Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation. Exp Cell Res 315(10):1759-1771
115. Choi U, Jee B, Lim Y, Lee K (2009) KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells. Cell Biochem Funct 27:40-47
116. Huang H, Groth J, Sossey-Alaoui K et al (2005) Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res 11(12):4357-4364 (Pubitemid 40825624)
117. Christgen M, Bruchhardt H, Ballmaier M et al (2008) KAI1/ CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. Int J Cancer 123(10):2239-2246
118. Christgen M, Christgen H, Heil C et al (2009) Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer. Cancer Sci 100(9):1767-1771
119. Takaoka A, Hinoda Y, Sato S et al (1998) Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res 89:397-404 (Pubitemid 28226920)
120. Yang JM, Peng ZH, Si SH et al (2008) KAI1 gene suppresses invasion K (2006) Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25(16):2367-2378
121. Bari R, Zhang YH, Zhang F et al (2009) Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol 174(2):647-660 [Epub 2008 Dec 30]
122. Xu JH, Guo XZ, Ren LN et al (2008) KAI1 is a potential target for anti-metastasis in pancreatic cancer cells. World J Gastroenterol 14(7):1126-1132
123. Bandyopadhyay S, Zhan R, Chaudhuri A et al (2006) Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 12:933-938 (Pubitemid 44175145)
124. He B, Liu L, Cook GA, Grgurevich S, Jennings LK, Zhang XA (2005) Tetraspanin CD82 attenuates cellular morphogenesis through down regulating integrin alpha-6 mediated cell adhesion. J Biol Chem 280(5):3346-3354 (Pubitemid 40223797)
125. Odintsova E, Sugiura T, Berditchevski F (2000) Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 10:1009-1012
126. Sridhar SC, Miranti CK (2006) Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25(16):2367-2378
127. Bass R, Werner F, Odintsova E, Sugiura T, Berditchevski F, Ellis V (2005) Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J Biol Chem 280(15):14811-14818 (Pubitemid 40562830)
128. Odintsova E, Butters T, Monti E et al (2006) Gangliosides play an important role in the organization of CD82-enriched microdomains. Biochem J 400:315-325 (Pubitemid 44852044)
129. Todeschini AR, Dos Santos JN, Handa K et al (2007) Ganglioside GM2/tetraspanin CD82 complex inhibits Met activation, and its cross-talk with integrins: basis for control of cell motility through glycosynapse. J Biol Chem 282:8123-8133 (Pubitemid 47093583)
130. Xu C, Zhang YH, Thangavel M, Richardson MM et al (2009) CD82 endocytosis and cholesterol-dependent reorganization of tetraspanin webs and lipid rafts. FASEB J 10:3273-3288
131. CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 278:27319-27328 (Pubitemid 36876890)
132. Takahashi M, Sugiura T, Abe M et al (2007) Regulation of c-MET signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration. Int J Cancer 121:1919-1929 (Pubitemid 47463154)
133. Jee BK, Park KM, Surendran S et al (2006) KAI1/CD82 suppresses tumor invasion by MMP9 inactivation via TIMP1 up-regulation in the H1299 human lung carcinoma cell line. Biochem Biophys Res Commun 342:655-661 (Pubitemid 43289040)
134. Berditchevski F, Odintsova E (2007) Tetraspanins as regulators of protein trafficking. Traffic 8:89-96 (Pubitemid 46099996)
135. Arduise C, Abache T, Li L et al (2008) Tetraspanins regulate ADAM10-mediated cleavage of TNF-alpha and epidermal growth factor. J Immunol 181:7002-7013
136. Xu D, Sharma C, Hemler ME (2009) Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J 23:3674-3681
137. Wakabayashi T, Craessaerts K, Bammens L et al (2009) Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat Cell Biol 11:1340-1346
138. Lee SA, Lee SY, Cho IH et al (2008) Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest 118:1354-1366